Details of the Drug Reposition

General Information of This Drug (ID: DM7HUNW)

• Drug Name: Testosterone (DM7HUNW)
• Synonyms: AndroGel; Androderm; Androlin; Andronaq; Andropatch; Androsorb; Andrusol; Depotest; Halotensin; Homosteron; Homosterone; Intrinsa; LibiGel; Malerone; Mertestate; Neotestis; Oreton; Orquisteron; Perandren; Primotest; Primoteston; Relibra; Striant; Sustanon; Sustanone; Teslen; Testandrone; Testaqua; Testiculosterone; Testim; Testobase; Testoderm; Testogel; Testolin; Testopropon; Testosteroid; Testosteron; Testosterona; Testosteronum; Testostosterone; Testoviron; Testrone; Testryl; Virormone; Virosterone; Beta testosterone; Cristerona T; Cristerone T; Malogen in Oil; Oreton F; Percutacrine androgenique; Synandrol F; Testoderm Tts; Testopel Pellets; Testosterone and its esters; Testosterone hydrate; Testosterone solution; Testoviron Schering; Testoviron T; Testro AQ; Virilon IM; AA 2500; Andro 100; Andronate 100; Andronate 200; Andropository 200; Andryl 200; CDB 111C; CMC_13449; COL 1621; CP 601B; Everone 200; Sustason 250; Testamone 100; Testred Cypionate 200; Androderm (TN); Androgel (TN); Geno-cristaux gremy; Malestrone (amps); Malogen, aquaspension injection; Neo-Hombreol F; Neo-testis; Oreton-F; Scheinpharm Testone-Cyp; Striant (TN); T-Cypionate; Testim (TN); Testoject-50; Testosterona [INN-Spanish]; Testosterone [Androgenic steroids, anabolic]; Testosterone [INN:BAN]; Testosteronum [INN-Latin]; Trans-Testosterone; Testosterone (JAN/USP); Testrin-P.A; Delta4-Androsten-17beta-ol-3-one; Delta4-androsten-17b-ol-3-one; Androst-4-en-17beta-ol-3-one; Delta(sup 4)-Androsten-17(beta)-ol-3-one; (17beta)-17-Hydroxyandrost-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-Hydroxy-(17beta)-androst-4-en-3-one; 17-Hydroxy-4-androsten-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 17b-hydroxy-4-androsten-3-one; 17beta-Hydroxy-3-oxo-4-androstene; 17beta-Hydroxy-4-androsten-3-one; 17beta-Hydroxy-delta(sup4)-androsten-3-one; 17beta-Hydroxyandrost-4-en-3-one; 17beta-Hydroxyandrost-4-ene-3-one; 4-Androsten-17-ol-3-one; 4-Androsten-17beta-ol-3-one; 4-androstene-17beta-ol-3-one; 7-beta-Hydroxyandrost-4-en-3-one
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

7 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Woodhouse-Sakati syndrome	DISHLVWB	N.A.	Approved	[1]
Hypopituitarism	DIS1QT3G	N.A.	Approved	[1]
Hypogonadotropic hypogonadism	DIS8JSKR	N.A.	Approved	[1]
Hypogonadism	DISICMNI	5A61.0	Approved	[1]
Multiple sclerosis	DISB2WZI	8A40	Approved	[1]
Osteoporosis	DISF2JE0	FB83.0	Approved	[2]
Hot flushes	DISAX6J3	GA30	Approved	[1]

2 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Choanal atresia-athelia-hypothyroidism-delayed puberty-short stature syndrome	DISZOS19	N.A.	Withdrawn	[3]
Cryptorchidism	DISYUD2P	N.A.	Withdrawn	[4]

1 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
High blood pressure	DISY2OHH	BA00	Discontinued in Phase 3	[5]

1 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Klinefelter syndrome	DISOUI7W	N.A.	Discontinued in Phase 2	[6]

2 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hypogonadism, male	DISV1F5R	N.A.	Investigative	[1]
Male hormonal deficiency	DISVN0YV	5A81	Investigative	[7]

References

• [1] Testosterone FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2858).
• [3] Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
• [4] ClinicalTrials.gov (NCT00963664) Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
• [5] Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
• [6] Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)
• [7] Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24.